2310008H09Rik Activators
The discovery of these activators typically begins with a comprehensive high-throughput screening (HTS) process, which involves the methodical testing of vast libraries of compounds for their ability to modulate gene expression. This screening employs sophisticated assays that utilize a reporter gene linked to the 2310008H09Rik gene promoter. When a compound successfully interacts with this promoter, it leads to an activation that results in a measurable output from the reporter gene-commonly a luminescent or fluorescent signal. The intensity of this output directly correlates with the degree of gene activation, hence providing a quantifiable means of assessing the efficacy of the compounds. Those that induce a pronounced increase in the reporter activity are singled out for further study. This selection is based on their demonstrated potential to upregulate the gene's expression, and such compounds are advanced for more detailed analysis to validate their activity.
A significant elevation in mRNA levels, as compared to control samples, indicates that the compound can indeed enhance gene expression at the transcriptional level. Furthermore, to verify that this increase in mRNA translates into a proportional increase in protein production, Western blot analysis is employed. This method allows for the detection and quantification of the protein product of the 2310008H09Rik gene. If an increase in protein levels is observed alongside the mRNA rise, this gives strong evidence of the compound's efficacy as an activator. The combination of qPCR and Western blotting is crucial to confirm that the chemical agent is not only upregulating mRNA but also effectively leading to an increase in the production of the corresponding protein, thereby providing a comprehensive view of the compound's influence on gene expression.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a nonspecific inhibitor of phosphodiesterases, enzymes that break down cAMP and cGMP. By preventing the degradation of cAMP, IBMX indirectly maintains an elevated level of PKA activity, which could phosphorylate and enhance the activity of the 2310008H09Rik protein. | ||||||
Zinc | 7440-66-6 | sc-213177 | 100 g | $48.00 | ||
ZnCl2 is a zinc ion provider and can act as a signaling molecule. Zinc ions can modulate the activity of various signaling proteins, including kinases and phosphatases that could be involved in the regulation of the 2310008H09Rik protein function. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride inhibits glycogen synthase kinase-3 (GSK-3). Inhibition of GSK-3 can result in the activation of the Wnt signaling pathway, which may indirectly enhance the activity of the 2310008H09Rik protein through its downstream effects. | ||||||
Calcium dibutyryladenosine cyclophosphate | 362-74-3 | sc-482205 | 25 mg | $147.00 | ||
Dibutyryl cyclic-AMP is a cell-permeable cAMP analog that directly activates cAMP-dependent pathways such as PKA signaling. Activation of PKA could lead to phosphorylation events that enhance the function of the 2310008H09Rik protein. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic acid is a potent inhibitor of protein phosphatases PP1 and PP2A, leading to increased phosphorylation levels within the cell. This can indirectly result in the enhancement of phosphorylation-dependent functions of the 2310008H09Rik protein. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin is a protein synthesis inhibitor that can activate stress-activated protein kinases, including JNK and p38 MAPK. Activation of these kinases can modulate various signaling pathways, potentially affecting the functional activity of the 2310008H09Rik protein. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is an ionophore that increases intracellular calcium levels, leading to the activation of calcium-dependent signaling pathways. These pathways may enhance the functional activity of the 2310008H09Rik protein through calcium-sensitive interactions. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a potent activator of protein kinase C (PKC). PKC activation can lead to phosphorylation of substrates that may be involved in the regulation and activation of the 2310008H09Rik protein. | ||||||
H-89 dihydrochloride | 130964-39-5 | sc-3537 sc-3537A | 1 mg 10 mg | $94.00 $186.00 | 71 | |
H-89 is an inhibitor of PKA, and while it typically reduces PKA activity, its use can lead to compensatory cellular mechanisms that can paradoxically increase the functional activity of other proteins through alternative pathways, potentially including the 2310008H09Rik protein. | ||||||